再鼎医药(09688.HK)“卫力迦”获国家药监局批准用于治疗全身型重症肌无力患者

阿斯达克财经07-16

再鼎医药(09688.HK) (ZLAB.US) 公布，与argenx(ARGX.US) 合作的艾加莫德皮下注射“卫力迦”，其生物制品上市许可申请已获得国家药监局批准，与常规治疗药物联合，用于治疗乙酰胆堿受体(AChR)抗体阳性的成人全身型重症肌无力(gMG)患者。再鼎医药总裁兼全球研发负责人Rafael G. Amado表示，非常高兴国家药监局批准卫力迦的上市申请，将可为中国gMG患者提供另...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2451953201?lang=zh_CN&edition=full","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230802095624300_s.jpg","is_english":false,"pubTime":"2024-07-16 14:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2451953201","market":"sh","top_or_hot":-1,"title":"再鼎医药(09688.HK)“卫力迦”获国家药监局批准用于治疗全身型重症肌无力患者","media":"阿斯达克财经","content":"<div>\n<p>再鼎医药(09688.HK) (ZLAB.US)  公布，与argenx(ARGX.US)  合作的艾加莫德皮下注射“卫力迦”，其生物制品上市许可申请已获得国家药监局批准，与常规治疗药物联合，用于治疗乙酰胆堿受体(AChR)抗体阳性的成人全身型重症肌无力(gMG)患者。再鼎医药总裁兼全球研发负责人Rafael G. Amado表示，非常高兴国家药监局批准卫力迦的上市申请，将可为中国gMG患者提供另...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1363972/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>再鼎医药(09688.HK)“卫力迦”获国家药监局批准用于治疗全身型重症肌无力患者</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n再鼎医药(09688.HK)“卫力迦”获国家药监局批准用于治疗全身型重症肌无力患者\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-16 14:33 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1363972/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>再鼎医药(09688.HK) (ZLAB.US)  公布，与argenx(ARGX.US)  合作的艾加莫德皮下注射“卫力迦”，其生物制品上市许可申请已获得国家药监局批准，与常规治疗药物联合，用于治疗乙酰胆堿受体(AChR)抗体阳性的成人全身型重症肌无力(gMG)患者。再鼎医药总裁兼全球研发负责人Rafael G. Amado表示，非常高兴国家药监局批准卫力迦的上市申请，将可为中国gMG患者提供另...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1363972/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1363972/latest-news/AAFN","article_id":"2451953201","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230802095624300_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2451953201","pubTimestamp":1721111580,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"再鼎医药公布，与argenx合作的艾加莫德皮下注射“卫力迦”，其生物制品上市许可申请已获得国家药监局批准，与常规治疗药物联合，用于治疗乙酰胆堿受体抗体阳性的成人全身型重症肌无力患者。再鼎医药总裁兼全球研发负责人Rafael G. Amado表示，非常高兴国家药监局批准卫力迦的上市申请，将可为中国gMG患者提供另一种FIC的治疗选择，除提升疗程的灵活性外，亦有望进一步简化治疗方案，让治疗的可及性提高。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","BK1588":"回港中概股","09688":"再鼎医药"},"translate_title":"Zai Lab (09688. HK) \"Weilijia\" was approved by the State Food and Drug Administration for the treatment of patients with generalized myasthenia gravis","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":1},"content_text":"再鼎医药(09688.HK) (ZLAB.US)  公布，与argenx(ARGX.US)  合作的艾加莫德皮下注射“卫力迦”，其生物制品上市许可申请已获得国家药监局批准，与常规治疗药物联合，用于治疗乙酰胆堿受体(AChR)抗体阳性的成人全身型重症肌无力(gMG)患者。再鼎医药总裁兼全球研发负责人Rafael G. Amado表示，非常高兴国家药监局批准卫力迦的上市申请，将可为中国gMG患者提供另一种FIC的治疗选择，除提升疗程的灵活性外，亦有望进一步简化治疗方案，让治疗的可及性提高。公司又指，艾加莫德皮下注射目前正在探索在其他自身免疫性疾病中的潜在治疗应用。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-16 12:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)AASTOCKS新闻","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2451953201"}